BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22571196)

  • 1. Treatment of chronic hypercalcemia.
    Camozzi V; Luisetto G; Basso SM; Cappelletti P; Tozzoli R; Lumachi F
    Med Chem; 2012 Jul; 8(4):556-63. PubMed ID: 22571196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment of malignancy-associated hypercalcemia.
    Lumachi F; Brunello A; Roma A; Basso U
    Curr Med Chem; 2008; 15(4):415-21. PubMed ID: 18288996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant hypercalcemia.
    Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
    Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of malignancy associated hypercalcemia].
    Tai N; Inoue D
    Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
    Tai N; Inoue D
    Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of malignancy-associated hypercalcemia].
    Endo I; Inoue D
    Clin Calcium; 2006 Apr; 16(4):665-69. PubMed ID: 16582519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology and management of severe hypercalcemia.
    Nussbaum SR
    Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
    Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
    Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-induced hypercalcemia.
    Lumachi F; Brunello A; Roma A; Basso U
    Anticancer Res; 2009 May; 29(5):1551-5. PubMed ID: 19443365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.
    Roux S; Massicotte MH; Huot Daneault A; Brazeau-Lamontagne L; Dufresne J
    Bone; 2019 Mar; 120():482-486. PubMed ID: 30572144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypercalcemia of malignancy: clinical features, diagnosis and treatment].
    Farias ML
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):816-24. PubMed ID: 16444366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercalcemia: an evidence-based approach to clinical cases.
    Assadi F
    Iran J Kidney Dis; 2009 Apr; 3(2):71-9. PubMed ID: 19395781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignancy-associated hypercalcemia].
    Oura S
    Nihon Rinsho; 2003 Jun; 61(6):1006-9. PubMed ID: 12806951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy.
    Onuma E; Sato K; Saito H; Tsunenari T; Ishii K; Esaki K; Yabuta N; Wakahara Y; Yamada-Okabe H; Ogata E
    Anticancer Res; 2004; 24(5A):2665-73. PubMed ID: 15517871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
    Harsch IA; Konturek PC
    Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical approach to hypercalcemia.
    Carroll MF; Schade DS
    Am Fam Physician; 2003 May; 67(9):1959-66. PubMed ID: 12751658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
    Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
    Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
    Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypercalcemia of malignancy in the palliative care patient: a treatment strategy.
    Kovacs CS; MacDonald SM; Chik CL; Bruera E
    J Pain Symptom Manage; 1995 Apr; 10(3):224-32. PubMed ID: 7543127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.